The DOI matches its Crossref record; 68 of the 68 references it cites were found in a registry or an index.
Modeling pulmonary fibrosis with bleomycin
Abstract
PURPOSE OF REVIEW: Idiopathic pulmonary fibrosis is a chronic pulmonary disease of unknown origin ultimately leading to death. No treatment exists yet and animal models have been employed in order to elucidate its etiopathogenesis. Here, we summarize the characteristics of the bleomycin animal model, the most commonly used model of pulmonary fibrosis, highlighting recent advances it has led us to despite its disadvantages. RECENT FINDINGS: Repetitive intratracheal administration of bleomycin more effectively mimics the chronic aspect of pulmonary fibrosis, as well as other characteristics including the presence of hyperplastic alveolar epithelial cells. Epithelial-to-mesenchymal transition seems to be a major contributor to the lung fibroblast population. There is growing evidence that macrophages, as well as fibrocytes, are largely involved in disease progression by mediating fibroblast and myofibroblast activation. In addition, molecules involved in phospholipid homeostasis are now becoming more appealing as potential therapeutic targets. SUMMARY: Despite its disadvantages, the bleomycin animal model remains the best available experimental tool for studying disease pathogenesis and testing of novel pharmaceutical compounds. Two such compounds currently showing some promise in clinical trials have emerged through the bleomycin model and preliminary results of basic research using this model have shown that more candidate compounds may follow in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Gene Ontology: tool for the unification of biology
Ashburner, M., Ball, C. A., Blake, J. A., Botstein, D., Butler, H., Cherry, J. M., Davis, A. P., Dolinski, K., Dwight, S. S., Eppig, J. T., et al. (2000) · Nature Genetics · doi:10.1038/75556 · Cited by 43,206
The basics of epithelial-mesenchymal transition
Kalluri, R., & Weinberg, R. A. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39104 · Cited by 10,196
Epithelial-mesenchymal transition and its implications for fibrosis
Kalluri, R., & Neilson, E. G. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200320530 · Cited by 2,649
Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
Ashcroft, T., Simpson, J. M., & Timbrell, V (1988) · Journal of Clinical Pathology · doi:10.1136/jcp.41.4.467 · Cited by 1,680
Kim, K. K., Kugler, M. C., Wolters, P. J., Robillard, L., Galvez, M. G., Brumwell, A. N., Sheppard, D., & Chapman, H. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0605669103 · Cited by 1,257
Moeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
miR-21 mediates fibrogenic activation of pulmonary fibroblasts and lung fibrosis
Liu, G., Friggeri, A., Yang, Y., Milosevic, J., Ding, Q., Thannickal, V. J., Kaminski, N., & Abraham, E. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100035 · Cited by 935
Tager, A. M., LaCamera, P., Shea, B. S., Campanella, G. S., Selman, M., Zhao, Z., Polosukhin, V., Wain, J., Karimi-Shah, B. A., Kim, N. D., et al. (2008) · Nature Medicine · doi:10.1038/nm1685 · Cited by 823
Murine models of pulmonary fibrosis
Moore, B. B., & Hogaboam, C. M. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00313.2007 · Cited by 796
Inhibition and Role of let-7d in Idiopathic Pulmonary Fibrosis
Pandit, K. V., Corcoran, D., Yousef, H., Yarlagadda, M., Tzouvelekis, A., Gibson, K. F., Konishi, K., Yousem, S. A., Singh, M., Handley, D., et al. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200911-1698oc · Cited by 506
Cited by
Flow Cytometric Analysis of Macrophages and Dendritic Cell Subsets in the Mouse Lung
Misharin, A. V., Morales-Nebreda, L., Mutlu, G. M., Budinger, G. R. S., & Perlman, H. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0086ma · Cited by 838
Inflammation and immunity in IPF pathogenesis and treatment
Heukels, P., Moor, C. C., von der Thüsen, J. H., Wijsenbeek, M. S., & Kool, M. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.12.015 · Cited by 517
The Bleomycin Model of Pulmonary Fibrosis
Liu, T., De Los Santos, F. G., & Phan, S. H. (2017) · Methods in Molecular Biology · doi:10.1007/978-1-4939-7113-8_2 · Cited by 357
Schiller, H. B., Fernandez, I. E., Burgstaller, G., Schaab, C., Scheltema, R. A., Schwarzmayr, T., Strom, T. M., Eickelberg, O., & Mann, M. (2015) · Molecular Systems Biology · doi:10.15252/msb.20156123 · Cited by 261
Mice with Pulmonary Fibrosis Driven by Telomere Dysfunction
Povedano, J. M., Martinez, P., Flores, J. M., Mulero, F., & Blasco, M. A. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.028 · Cited by 225
“However, upon removal of the treatment, these lesions do not progress in time, and many of them eventually regress, most likely owing to lung regeneration by the non-affected cells (Mouratis and Aidinis, 2011).”
Background
Metadata
- Authors
- Mouratis, M. A., & Aidinis, V.
- Venue
- Current Opinion in Pulmonary Medicine
- Published
- 2011-09
- Volume
- 17
- Issue
- 5
- Pages
- 355-361
- ISSN
- 1070-5287 (ISSN-L)
- OpenAlex
- W2054017711
- Cited by
- 311
- References
- 68
- FWCI
- 13.61
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Modeling pulmonary fibrosis with bleomycin. https://app.cochat.ai/papers/10.1097/mcp.0b013e328349ac2b
- The paper
- Mouratis, M. A., & Aidinis, V. (2011). Modeling pulmonary fibrosis with bleomycin. Current Opinion in Pulmonary Medicine. https://doi.org/10.1097/mcp.0b013e328349ac2b
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
